PFE Pfizer, Inc.
Healthcare · Drug Manufacturers - General
26.62
-1.59%
About the company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
52-week range
Dividend deep dive
Pfizer, Inc. (PFE), a healthcare company specializing in drug manufacturing, currently has a dividend yield of 6.87%. This yield is positioned near the high end of its 5-year range, which spans from 3.24% to 6.9%. The company's dividend safety is categorized as "at_risk," indicating potential challenges. However, based on Yield Theory, the stock's current price of $25.05 appears to be at a "fair" valuation, implying a price of $35.25.
Dividend history
Pfizer has a record of 16 consecutive years of dividend increases, granting it a "contender" status in the CCC list. Over the past three years, the dividend has grown at a compound annual growth rate (CAGR) of 2.44%, while the 5-year CAGR stands at 3.59%. The annual dividend has steadily risen from $0.9867 in 2014 to $1.68 in 2024, with a projected dividend of $1.72 for 2025. This history demonstrates consistent, albeit moderate, dividend growth.
Dividend safety
The company's dividend safety status is "at_risk," largely due to a high payout ratio of 131.3%. This figure is derived from the current annual dividend of $1.72 relative to earnings per share (EPS) of $1.31.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.
Price history
Dividend profile
Yield band A stock's current dividend yield shown against its own range over the past five years — the low, average and high. Near the high end the shares look relatively cheap for the income they pay; near the low end, relatively expensive. It's the picture behind Dividend Yield Theory. Learn more → (5-year)
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Held by 8 investors · watched by 3
Appears in these lists
PFE qualifies for these curated dividend rankings.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track PFE and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →